The short version of BPC-157 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-20. Anything still debated is marked as such rather than presented as settled.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Approximate, for sequence GEPPPGKPADDAGLV |
| Molecular mass | ~1419 Da | Neutral form |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Typical storage | -20 C | Dry powder, protected from moisture |
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
== Sample preparation == For most clinical methods using ICP-MS, there is a relatively simple and quick sample prep process. The main component to the sample is an internal standard, which also serves as the diluent. This internal standard consists primarily of deionized water, with nitric or hydrochloric acid and indium and/or gallium. The addition of volatile acids allows for the sample to decompose into its gaseous components in the plasma which minimizes the ability for concentrated salts and solvent loads to clog the cones and contaminate the instrument. Depending on the sample type, usually 5 mL of the internal standard is added to a test tube along with 10–500 microliters of sample. This mixture is then vortexed for several seconds or until mixed well and then loaded onto the autosampler tray. For other applications that may involve very viscous samples or samples that have particulate matter, a process known as sample digestion may have to be carried out before it can be pipetted and analyzed. This adds an extra first step to the above process and therefore makes the sample prep more lengthy.
=== Cryopreserved red blood cells === To increase the availability of RBCs of rare blood types, red blood cells can be stored cryopreserved (frozen) instead of refrigerated. With a controlled, standardised freezing and thawing process, the red blood cells can be stored in frozen condition for up to 30 years. Also for cryopreservation, cell processors are frequently used for both the pre-freezing glycerolisation procedure and for washing away the glycerol after thawing of the red blood cells. Using an automated device allows for standardised processing to ensure optimal protection from ice crystal formation, which otherwise could damage the red blood cells. There are two general approaches for RBC cryopreservation, referred to as the high- and the low-glycerol method. Glycerol serves as cryoprotectant in both. The high-glycerol method uses 40% weight/volume glycerol, a slow freezing rate (1–3 °C per minute) and allows storage of the frozen red blood cells in common mechanical −60–80 °C freezers. The low-glycerol method is based on 20% weight/volume glycerol and demands plunge freezing in (−150 °C) liquid nitrogen. Because of the extreme storage temperature, the low-glycerol method is not compatible with the PVC tubes of blood bags. PVC tubes are essential for sterile docking; a technology which maintains a closed system after thawing and, thereby, allows a longer post-thawing shelf-life.
== Signs and symptoms == Hyperglycemia may be asymptomatic. Blood glucose levels can rise above normal and cause pathological and functional changes for significant periods without producing any permanent effects or symptoms. The degree of hyperglycemia can change over time depending on the metabolic cause, for example, impaired glucose tolerance or fasting glucose, and it can depend on treatment. The following symptoms may be associated with acute or chronic hyperglycemia, with the first three composing the classic hyperglycemic triad:
Sources: en.wikipedia.org
=== Fractional base units and referenced KMD plots === Kendrick mass defect plots created by using fractional base units exhibit enhanced resolution. Referenced Kendrick mass defect plots (KMD plots referenced to the terminal group and adduct composition) with fractional base units can be used to obtain an overview of copolymer composition.
During 1988, it became apparent to the Soviets that oil and gas subsidies, along with the cost of maintaining massive troops levels, represented a substantial economic drain. In addition, the security advantage of a buffer zone was recognized as irrelevant and the Soviets officially declared that they would no longer intervene in the affairs of satellite states in Central and Eastern Europe. George H. W. Bush and Gorbachev met at the Moscow Summit in May 1988 and the Governors Island Summit in December 1988. In 1989, Soviet forces withdrew from Afghanistan without achieving their objectives. Later that year, the Berlin Wall, the Inner German border and the Iron Curtain fell. On 3 December 1989, Gorbachev and Bush declared the Cold War over at the Malta Summit. In February 1990, Gorbachev agreed with the US-proposed Treaty on the Final Settlement with Respect to Germany and signed it on 12 September 1990, paving the way for the German reunification. When the Berlin Wall came down, Gorbachev's "Common European Home" concept began to take shape. The two former adversaries were partners in the Gulf War against Iraq (August 1990 – February 1991). During the final summit in Moscow in July 1991, Gorbachev and Bush signed the START I arms control treaty.
=== January === January 13, 2009: South Korea, Taiwan, Japan, United States Global shipping experiences a drop in trade, as exports from South Korea dropping an annualised 30%, with Taiwan and Japan experiencing a 42% and 27% drop respectively. Outgoing traffic in the United States dropped 18% from Long Beach and Los Angeles.
==== Progressive multiple sclerosis ==== In 2011, mitoxantrone was the first medication approved for secondary progressive MS. In this population, tentative evidence supports mitoxantrone moderately slowing the progression of the disease and decreasing rates of relapses over two years. In 2026, tolebrutinib, a BTK inhibitor, was approved for non-relapsing secondary MS in the EU. It reduces the activity of microglia, immune cells in the brain, as well as of B cells. New approved medications continue to emerge. In March 2017, the FDA approved ocrelizumab as a treatment for primary progressive MS in adults, the first drug to gain that approval. It is also used for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. According to a 2021 Cochrane review, ocrelizumab may reduce worsening of symptoms for primary progressive MS and probably increases unwanted effects but makes little or no difference to the number of serious unwanted effects. In 2019, siponimod and cladribine were approved in the United States for the treatment of secondary progressive multiple sclerosis (SPMS). Subsequently, ozanimod was approved in 2020, and ponesimod was approved in 2021, which were both approved for management of CIS, relapsing MS, and SPMS in the U.S., and RRMS in Europe. Ocrelizumab/hyaluronidase was approved for medical use in the United States in September 2024.
Sources: en.wikipedia.org
The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.
No. The gastric protein is larger, while BPC-157 is a short fragment sequence. The peptide is produced synthetically for research use. The relationship is one of sequence origin, not chemical identity.
It is most often supplied as a lyophilized powder, frequently as the acetate salt. The powder is reconstituted with water or a buffer before use. Free-base and other salt forms also exist but are less common in catalogs.
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.